Drilldown: Medicines

25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allylescaline (1) · Bromo-DragonFLY (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Escaline (1) · Ketotifen (1) · Methallylescaline (1) · Olopatadine (1) · Proscaline (1) · TMA-2 (1)

None (25) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal) (1) · Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) · '"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1)

None (26) · '"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1) · '"`UNIQ--vote-00001286-QINU`"' (1)

None (26) · Ophthalmic 1 drop in each eye every 8-12 hours (1) · Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)

None (26) · 0.025%, 0.035% ophthalmic solutions (1) · 0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1)

None (26) · 1 drop per eye q8-12h (1) · Once daily (Pataday 0.7%); BID (other ophthalmic) (1)

None (25) · insufflated (1) · intranasal (1) · Oral (1) · PR (1) · Topical ophthalmic (2)

None (25) · 45-75 min (oral) (1) · Symptom relief within 30-60 minutes (1) · Within minutes (1)

None (25) · 24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) · 4-8 h (1) · 8-12 hours (1)

None (25) · Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) · Not well characterized (1) · ~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1)

None (25) · Not well characterized (1) · Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1)

None (25) · Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (25) · OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) · OTC in US (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)